Author: Ken Dropiewski

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting

Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals MENLO PARK, Calif., Nov. 2, 2023 /PRNewswire/ — MyOme, Inc….

Silk Road Medical Names Chas McKhann Chief Executive Officer

Accomplished Leader with Over 25 Years of Medical Device Industry Experience SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed […]

Volta Medical Named Best Startup at Prix Galien USA Awards 2023

Widely considered the industry’s highest accolade for life sciences research and development, the Prix Galien Awards honor innovative treatments and technologies that improve human health MARSEILLE, France, Nov. 02, 2023 (GLOBE NEWSWIRE) — Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in […]

FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platform

AUCKLAND, New Zealand–(BUSINESS WIRE)–Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology. The CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive evaluation for risk of cardiovascular disease (CVD) using fundus retinal image

Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced results from a pooled analysis of DETOUR1 and DETOUR2 Studies evaluating Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System. PTAB with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral art

Teleflex Announces Quarterly Dividend

WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2023, to shareholders of record at the close of business on […]

Teleflex Reports Third Quarter Financial Results and Full Year 2023 Outlook

WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023. Third quarter financial summary Revenues of $746.4 million, up 8.7% compared to the prior year period; up 7.4% on a constant currency basis  GAAP diluted EPS […]

Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System

GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study. MARRS is a multi-center trial to evaluate the performance of the Millipede System. The first patient was enrolled at Stony Brook University Hospital in Stony Brook, NY. “I am delighted to begin enrollment in the MARR